Log in
NASDAQ:ADMA

ADMA Biologics Stock Forecast, Price & News

$2.18
+0.14 (+6.86 %)
(As of 09/25/2020 12:00 AM ET)
Add
Compare
Today's Range
$2.02
Now: $2.18
$2.20
50-Day Range
$2.04
MA: $2.58
$3.13
52-Week Range
$1.45
Now: $2.18
$5.25
Volume1.86 million shs
Average Volume3.74 million shs
Market Capitalization$188.24 million
P/E RatioN/A
Dividend YieldN/A
Beta1.98
ADMA Biologics, Inc., a biopharmaceutical and specialty immunoglobulin company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease. The company also offers Nabi-HB, a hyperimmune globulin for the treatment of acute exposure; and Bivigam, an intravenous immune globulin for the treatment of primary humoral immunodeficiency. In addition, it operates source plasma collection facilities in Norcross, Marietta, and Kennesaw, Georgia. The company distributes its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was founded in 2004 and is headquartered in Ramsey, New Jersey.
Read More
ADMA Biologics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.23 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ADMA
CUSIPN/A
Phone201-478-5552

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$29.35 million
Book Value$0.44 per share

Profitability

Net Income$-48,280,000.00
Net Margins-164.90%

Miscellaneous

Employees314
Market Cap$188.24 million
Next Earnings Date11/4/2020 (Estimated)
OptionableOptionable
$2.18
+0.14 (+6.86 %)
(As of 09/25/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ADMA News and Ratings via Email

Sign-up to receive the latest news and ratings for ADMA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











ADMA Biologics (NASDAQ:ADMA) Frequently Asked Questions

How has ADMA Biologics' stock price been impacted by COVID-19?

ADMA Biologics' stock was trading at $2.31 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ADMA stock has decreased by 5.6% and is now trading at $2.18.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of ADMA Biologics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ADMA Biologics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for ADMA Biologics
.

When is ADMA Biologics' next earnings date?

ADMA Biologics is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for ADMA Biologics
.

How were ADMA Biologics' earnings last quarter?

ADMA Biologics Inc (NASDAQ:ADMA) released its quarterly earnings results on Wednesday, August, 5th. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.16) by $0.07. The biotechnology company earned $7.79 million during the quarter, compared to analyst estimates of $10.29 million. ADMA Biologics had a negative return on equity of 104.32% and a negative net margin of 164.90%.
View ADMA Biologics' earnings history
.

What price target have analysts set for ADMA?

3 analysts have issued 12 month price objectives for ADMA Biologics' stock. Their forecasts range from $6.00 to $12.00. On average, they anticipate ADMA Biologics' stock price to reach $8.00 in the next twelve months. This suggests a possible upside of 267.0% from the stock's current price.
View analysts' price targets for ADMA Biologics
.

Are investors shorting ADMA Biologics?

ADMA Biologics saw a increase in short interest during the month of August. As of August 31st, there was short interest totaling 13,310,000 shares, an increase of 12.0% from the August 15th total of 11,880,000 shares. Based on an average daily volume of 5,910,000 shares, the short-interest ratio is presently 2.3 days.
View ADMA Biologics' Short Interest
.

Who are some of ADMA Biologics' key competitors?

What other stocks do shareholders of ADMA Biologics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ADMA Biologics investors own include Matinas BioPharma (MTNB), Pennsylvania R.E.I.T. (PEI), OrganiGram (OGI), Gran Tierra Energy (GTE), Tilly's (TLYS), Cannabics Pharmaceuticals (CNBX), Novan (NOVN), AEterna Zentaris (AEZS), BioNano Genomics (BNGO) and Zosano Pharma (ZSAN).

Who are ADMA Biologics' key executives?

ADMA Biologics' management team includes the following people:
  • Mr. Adam S. Grossman, Co-Founder, Pres, CEO & Director (Age 42)
  • Dr. Jerrold B. Grossman Ph.D., D.P.S., Co-Founder & Vice Chairman (Age 71)
  • Mr. Brian Lenz CPA, CPA, Exec. VP & CFO (Age 47)
  • Dr. James Mond, Exec. VP, Chief Scientific Officer & Chief Medical Officer (Age 73)
  • Mr. James Hauert, Sr. VP of Commercialization & Strategy

What is ADMA Biologics' stock symbol?

ADMA Biologics trades on the NASDAQ under the ticker symbol "ADMA."

Who are ADMA Biologics' major shareholders?

ADMA Biologics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Prosight Management LP (1.50%), Marshall Wace LLP (1.05%), Motley Fool Asset Management LLC (0.78%), Goldman Sachs Group Inc. (0.69%), Schonfeld Strategic Advisors LLC (0.68%) and Essex Investment Management Co. LLC (0.53%). Company insiders that own ADMA Biologics stock include Adam S Grossman, Biotest Divestiture Trust, Brian Lenz, James Mond, Jerrold B Grossman, Lawrence P Guiheen, Life Sciences Maste Perceptive and Perceptive Advisors Llc.
View institutional ownership trends for ADMA Biologics
.

Which institutional investors are selling ADMA Biologics stock?

ADMA stock was sold by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Ikarian Capital LLC, Schonfeld Strategic Advisors LLC, Tudor Investment Corp Et Al, Avantax Advisory Services Inc., Charles Schwab Investment Management Inc., Telemetry Investments L.L.C., and SG Americas Securities LLC.
View insider buying and selling activity for ADMA Biologics
.

Which institutional investors are buying ADMA Biologics stock?

ADMA stock was purchased by a variety of institutional investors in the last quarter, including Essex Investment Management Co. LLC, Assenagon Asset Management S.A., Alyeska Investment Group L.P., Hudson Bay Capital Management LP, Leap Investments LP, Goldman Sachs Group Inc., AE Wealth Management LLC, and Principal Financial Group Inc.. Company insiders that have bought ADMA Biologics stock in the last two years include Adam S Grossman, Brian Lenz, James Mond, Jerrold B Grossman, Lawrence P Guiheen, Life Sciences Maste Perceptive, and Perceptive Advisors Llc.
View insider buying and selling activity for ADMA Biologics
.

How do I buy shares of ADMA Biologics?

Shares of ADMA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is ADMA Biologics' stock price today?

One share of ADMA stock can currently be purchased for approximately $2.18.

How big of a company is ADMA Biologics?

ADMA Biologics has a market capitalization of $188.24 million and generates $29.35 million in revenue each year. The biotechnology company earns $-48,280,000.00 in net income (profit) each year or ($0.92) on an earnings per share basis. ADMA Biologics employs 314 workers across the globe.

What is ADMA Biologics' official website?

The official website for ADMA Biologics is www.admabiologics.com.

How can I contact ADMA Biologics?

ADMA Biologics' mailing address is 465 STATE ROUTE 17, RAMSEY NJ, 07446. The biotechnology company can be reached via phone at 201-478-5552 or via email at [email protected]

This page was last updated on 9/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.